Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
CRISPR Therapeutics (CRSP) presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and ...
瑞士楚格和美国波士顿 - 市值43亿美元的基因医学领导者CRISPR Therapeutics (NASDAQ:CRSP)报告了其正在进行的CTX112™用于CD19阳性B细胞恶性肿瘤的1/2期临床试验取得重大进展。根据InvestingPro数据,该公司保持强劲的财务状况,资产负债表上的现金多于债务。公司宣布,美国食品和药物管理局(FDA)授予CTX112再生医学先进疗法(RMAT)认定,用于治 ...
Recent research published in the journal “Science Bulletin” detailed the creation of a tool called ChCas12b that can ...
-Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R ...
Kevin Esvelt, an associate professor at the MIT Media Lab and the inventor of CRISPR-based gene drive, joins Radio Boston.
New genetic medicines for sickle cell disease were hailed as a milestone. Now researchers are working on ways to widen access ...
CRISPR是一种强大的基因编辑工具,它使用一种名为Cas9的酶对目标基因进行精确编辑。 但问题是,它并不总能留在身体的正确部位,而且在需要的很长时间后仍会继续编辑基因,从而可能引发免疫反应。一种新型癌症基因疗法可以在身体的特定部位远程激活。
A new kind of cancer gene therapy can be remotely activated at a specific part of the body. The team developed a version of ...
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% ...
立陶宛的研究人员展示了一种新的、更通用的基因编辑CRISPR系统的分子结构。 科学家们公布了著名基因编辑工具CRISPR的新版本,它可以暂时“暂停”一个给定的基因,而不是永久地关闭它。
A research group led by Jacob Corn has just discovered that the use of AZD7648 has serious side effects. The study has just ...